Purpose: PTEN-null tumors become dependent on the PI3Kb isoform and can be targeted by molecules such as the selective PI3Kb inhibitor AZD8186. However, beyond the modulation of the canonical PI3K pathway, the consequences of inhibiting PI3Kb are poorly defined.
Introduction
Signaling through the PI3K pathway plays an important role in regulating the growth and survival of many tumor types (1, 2) . Moreover, the PI3K pathway is mutated in many tumor types, with somatic mutations in either the kinases or associated regulatory molecules implicated in tumor initiation or progression (3) . The PI3K family consists of four class 1 isoforms p110a, p110b, p110d, and p110g. PI3Ka and b are expressed in most normal tissues. PI3Kd and PI3Kg are primarily expressed in the immune cells (2) .
In certain tumors, the PI3Kb isoform is proposed to play an important role in driving tumor progression, particularly in the context of a loss of the tumor suppressor PTEN (4) (5) (6) . Although the mechanism that creates this dependency is unclear, the switch is thought to be related to modulation of the basal cellular levels of PIP3 via constitutive basal activity of PI3Kb. In contrast, PI3Ka required activation through mutation of the catalytic or activated growth factor receptors (7) . Loss of PTEN protein can occur in multiple ways: deletion of one or both copies of the gene, mutation resulting in loss of function, epigenetic regulation, or by downregulation of protein by miRNA (2) . Reduction in levels of PTEN protein occurs in a number of tumor types, including triple-negative breast cancer (8) and prostate cancer (9, 10) . This is commonly associated with poor prognosis (5) . Finally, PI3Kb can be mutated (11, 12) , although this is a relatively rare event. PI3Kb can be activated via G-protein-coupled receptors regulating thrombin and ADP-mediated platelet aggregation (13, 14) , as well as LPA receptor-mediated signals via the small GTPase RAC (15) . Moreover, cells expressing mutant RAC can be dependent on PI3Kb for survival (16) .
This emerging role for PI3Kb in tumor progression has led to the development of various isoform inhibitors, including GSK2636771, SAR260301, and AZD8186, for the treatment of solid tumors (17) (18) (19) . Preclinically, these agents show preferential activity in cell lines or tumor models where PTEN protein is lost with treatment associated with suppression of canonical PI3K/AKT pathway biomarkers and translocation of the transcription factor FOXO to the nucleus (20, 21) . However, little is known about the other effects of PI3Kb targeting therapeutics in the context of PTEN protein loss. To identify other mechanisms that may contribute to the therapeutic benefit of PI3Kb inhibitors beyond the direct regulation of canonical PI3K/AKT/ mTOR survival pathway, we performed a hypothesis independent analysis of the effects of the PI3Kb inhibitor AZD8186 in PTEN-null tumors.
Materials and Methods

Cell line culture and reagents
Cells lines were grown in RPMI1640 buffer þ 10% FCS þ 2 mmol/L glutamine at 37 C, 5% carbon dioxide. Cell lines used for primary in vitro and in vivo experiments are listed in Supplementary Table S1 . All cell lines were authenticated at AstraZeneca cell banking using DNA fingerprinting short tandem repeat assays. All revived cells were used within 15 passages and cultured for less than 6 months. All inhibitors were dissolved in DMSO to a concentration of 10 mmol/L and stored under nitrogen.
siRNA knockdown experiments
The following ON-TARGETplus siRNAs were used: nontargeting control (D001810-10-05), FOXO3 (L-003007-00-0005), MYC (L-003282-02-0005), and HMGCS1 (L-009808-00-0005) (Dharmacon). The siRNAs were resuspended to 20 mmol/L in siRNA buffer (Dharmacon) and transfected using RNAiMAX and Opti-MEM (Thermo Fisher Scientific) according to the manufacturer's instructions.
Western blot analysis
Cells were lysed in RIPA buffer (Thermo Fisher Scientific) supplemented with 1Â Protease Inhibitor Cocktail (Roche), 1Â phosphatase inhibitor (Thermo Fisher Scientific), and 1:5,000 benzonase (Sigma-Aldrich), and equal amounts of protein were loaded and separated by SDS-PAGE. Horseradish peroxidaselinked secondary antibodies (GE Healthcare) and ECL or supersignal (Thermo Fisher Scientific) were used to detect immune complexes. For subcellular fractionation experiments, lysates were prepared using a Subcellular Protein Fractionation Kit for cells, according to the manufacturer's instructions (Thermo Fisher Scientific). Details of primary antibodies can be found in Supplementary Table S2 .
Cell proliferation assays
For the metabolite add-back proliferation assay, cells were fixed with 3.7% formaldehyde containing 0.1% Triton (Sigma-Aldrich) for 30 minutes at room temperature. Nuclei were stained with Hoechst (1:5,000, Thermo Fisher Scientific) in PBS for 30 minutes at room temperature. Cells were analyzed on a Cellomics Arrayscan (Thermo Fisher Scientific) using a cell count algorithm. Phasecontrast cell morphology images were taken using the IncuCyte (Essen Bioscience).
Antitumor experiments
All animal experiments were performed to the according to the UK Home Office. PC3 cells [ 3 , animals were randomized into control and treatment groups. Tumor volume was calculated twice weekly from bilateral caliper measurements using the formula length Â width Â width) Â p/6.
AZD8186 was generally formulated once weekly as a suspension in HPMC/Tween and dosed once or twice daily (0 and 6-8 hours). For groups where 1-aminobenzotriazole (ABT) was administered, AZD8186 was formulated once weekly either alone in 10% DMSO/60% TEG/30% WFI or in the presence of ABT at 10 mg/mL. For twice-daily dosing (0 and 6-8 hours), AZD8186 was codosed with ABT at 0 hour and administered alone as the single formulation at 6 to 8 hours.
Growth inhibition from the start of treatment was assessed by comparison of the geometric mean change in tumor volume for the control and treated groups. Statistical significance was evaluated using a one-tailed, two-sample t test.
Pharmacokinetic/pharmacodynamic studies
Total blood was collected by intracardiac puncture and plasma prepared and immediately frozen at À20 C for pharmacokinetic analysis. For each time point, a minimum of 4 or 5 tumors were snap frozen and used for protein and transcript analysis.
See Supplementary Methods for detailed methods. Briefly, tumors were lysed and protein concentration determined. For Western blot analysis, equal amounts of protein were loaded and separated by SDS-PAGE. Horseradish peroxidase-linked secondary antibodies and supersignal were used to detect immune complexes. Vehicle controls were used for normalizing biomarker signal for the treated samples. Pharmacokinetic data (free plasma concentration of the drug) were plotted with PI3K pathway biomarker data. Meso Scale Discovery and conventional ELISA assays are described in the Supplementary Methods.
RNA profiling and analysis
For in vitro experiments, total RNA was extracted using RNeasy kit (Qiagen). For xenograft models, cell pellets and tissues from xenograft models were snap frozen. Total RNA was extracted using miRNeasy Kit (Qiagen), with DNAse treatment, following the manufacturer's instructions. RNA quantity was assessed by NanoDrop 2000 (Thermo Fisher Scientific). Samples profiled for RNA sequencing (RNA-seq) were assessed for RNA integrity (RIN>7)
Translational Relevance
Loss of the tumor suppressor PTEN is common across many tumor types. These tumors can be sensitive to PI3K inhibitors, in particular inhibitors that target the PI3Kb isoform. Although pathway biomarkers, such as pAKT, are used to determine whether a compound is engaging target, little is known about the functional consequence of inhibiting PI3Kb signaling in these tumors. Here, a hypothesis-independent analysis reveals that PI3Kb inhibition in PTEN-null tumors has a broad impact on tumor metabolic endpoints, including reduction in expression of enzymes in the cholesterol biosynthesis pathway, reduction in the nucleotide pools, and an increase in cell stress. These represent novel mechanistic biomarkers for PI3Kb inhibitors that may inform whether sufficient pathway suppression is achieved, and also guide rational combination strategies for tumors with PTEN loss. using the RNA 6000 Nano Assay on the BioAnalyser (Agilent). Samples were sent for RNA-seq at Liverpool Centre for Genomic Research (Liverpool, United Kingdom). Total RNA was ribodepleted, and paired-end ScriptSeq library was performed and sequenced for 100 bp/100 M reads per sample.
One-step qRT-PCR was performed using the QuantiTect Probe Kit (Qiagen) according to the manufacturer's instructions. Realtime PCR analysis was performed on a LightCycler 480 (Roche). Details of the primer/probesets (Thermo Fisher Scientific) can be found in Supplementary Table S3 . See Supplementary Methods for detailed methods on Fluidigm profiling.
RNA-seq mapping and gene expression level estimation
Paired-end reads of length 100 bases were aligned to the human (GRCh37/hg19) and mouse (NCBI37/mm9) genomes separately using Bowtie in -n alignment mode as described previously (22, 23) . A custom Perl script was used to remove reads that mapped to both human and mouse genomes. Bowtie alignment format was converted to BED format using a custom Perl script, and this file used as input to "RPKM_count.py" from the RSeQC package to calculate an RPKM value across each gene present in both human and mouse annotation files downloaded from Ensembl version 71 (24) . The number of reads overlapping the same genes was calculated using the R Bioconductor package HTSeq (25) . Gene-specific expression analysis was performed using the Gene Set Enrichment Analysis (GSEA) package (26, 27) . Details of the gene sets are described in Supplementary Table S1 . Raw sequence data are available in the ArrayExpress database (www. ebi.ac.uk/arrayexpress) under accession number E-MTAB-4656.
Metabolomic analysis
Detailed methods for the metabolomic analysis are described in the Supplementary Methods and in ref. 28 .
Results
RNA-seq profiling of AZD8186-treated HCC70 tumor xenografts AZD8186 is an isoform-specific small-molecule PI3Kb inhibitor (18, 29) . In biochemical assays, AZD8186 potently inhibits PI3Kb (IC 50 4 nmol/L) and PI3Kd (IC 50 12 nmol/L) with selectivity over PI3Ka (IC 50 35 nmol/L) and PI3Kg (IC 50 675 nmol/L). We have previously shown that AZD8186 inhibits the growth of PTEN-null tumors, alone and in combination with docetaxel, androgen receptor blockade, and with PI3Ka inhibitors (18, 21, 30) .
To gain further insight into the consequences of suppressing PI3Kb signaling in the context of PTEN loss, animals bearing HCC70 tumors were treated with AZD8186 (100 mg/kg twice daily) for 5 days and sacrificed 2 hours after the 11th dose. Over this time course, there was a small change in tumor volume in the AZD8186-treated tumors (Fig. 1A) ; therefore, three tumors representative of the spread of size in each group were taken for subsequent RNA-seq analysis. AZD8186 treatment resulted in suppression of canonical PI3K pathway biomarkers, pAKT, Table S1 ). In addition, transcripts associated with cholesterol biosynthesis were reduced ( Fig. 1B and C) , and to a lesser extent transcripts associated with hypoxia, inflammation, and TNFa signaling ( Fig. 1B ; Supplementary Fig. S4A ). The changes in the murine compartment of the tumors were also analyzed. Changes in the stroma were less significant ( Supplementary Fig. S4B ), supporting the conclusion that the major impact of AZD8186 on tumor growth is through changes in signaling in the tumor cell compartment. The changes in the cholesterol biosynthesis genes were confirmed by quantitative RT-PCR together with an additional independent study where samples were taken 2 and 6 hours following the 11th dose of AZD8186 (Fig. 1D) . In both studies, there was a consistent downregulation of cholesterol biosynthesis pathway transcripts (Fig. 1E ).
AZD8186 downregulates expression of cholesterol biosynthesis pathway enzymes in PTEN-null cell lines
To confirm these data in PTEN-null cell lines. HCC70, LNCAP, and PC3 cells were treated with AZD8186 for 2, 24, and 48 hours ( Fig. 2A) , which resulted in suppression of canonical PI3K pathway biomarkers pAKT and pNDRG1. Across the three lines, HMGCS1 was strongly downregulated at 24 hours together with IDI1, MVD, and DHCR7. To confirm the dependency of PTENnull cell lines on the cholesterol biosynthesis pathway, HMGCS1 expression was reduced using siRNA ( Supplementary Fig. S7D ). Both HCC70 and LNCAP cell viability was reduced (Supplementary Fig. S7E and S7F). Expression of HMGCS1 was also downregulated by the AKT inhibitor AZD5363 and the mTORC1/2 inhibitor AZD2014, suggesting that the regulation of the pathway is mediated downstream of AKT/mTOR signaling ( To confirm the relevance of the cholesterol pathway for phenotypic and growth effects following AZD8186 treatment, the ability of cholesterol intermediates to recover the cell phenotype was examined. Despite the variability in efficiency of uptake into cells, recovery of the cell phenotype was observed following addition of mevalonate and geranylgeranyl pyrophosphate (Supplementary Fig. S6A ). As a positive control, the same intermediates were used to recover the cellular rounding induced by atorvastatin. Cholesterol did not rescue the morphology phenotype for either AZD8186 or atorvastatin, suggesting that the requirement of acetyl-coA into the cholesterol biosynthesis pathway in HCC70 cells is to generate GGPP ( Supplementary Fig.  S6B ). These data collectively suggest a link between the PI3Kb and cholesterol pathway; however, restoring the cholesterol pathway is not sufficient to drive proliferation.
FOXO3 and MYC, two transcription factors regulated by PI3K signaling, were modulated by AZD8186; FOXO3 nuclear localization increased, while levels of MYC nuclear and chromatinbound protein were reduced ( Fig. 2C; Supplementary Fig. S7B ; refs. [33] [34] [35] . To determine whether FOXO3 and MYC regulate HMGCS1 levels, FOXO3 and MYC expression were reduced in HCC70 and LNCAP cell lines. AZD8186 induces FOXO3 nuclear translocation; therefore, FOXO3 reduction would maintain HMGCS1 expression in the presence of AZD8186. Conversely, AZD8186 reduced MYC levels; therefore, reduction should result in loss of HMGCS1 expression. FOXO3 knockdown increased both the basal and AZD8186-treated expression levels of HMGCS1 ( Fig. 2D; Supplementary Fig. S7C ). MYC knockdown has a modest effect on the suppression of basal and AZD8186-treated expression of HMGCS1 and was not as effective as AZD8186. FOXO3 knockdown did not alter viability of control or AZD8186-treated HCC70 and LNCAP cells, whereas knockdown of MYC significantly impaired cell survival (Supplementary Fig. S7E and S7F ). These results suggest that downstream of the AKT pathway, FOXO3 can affect the expression of HMGCS1; however, it is likely that other transcription factors have a more pronounced influence on the pathway.
AZD8186 downregulates expression of cholesterol biosynthesis pathway enzymes in PTEN-null tumors
The effects of AZD8186 on cholesterol biosynthesis pathway protein expression in vivo in HCC70 xenografts treated with AZD8186 at 25 mg/kg twice daily for 7 days were analyzed by assessing HMGCS1, IDI1, and SQLE expression. Consistent with previous data, we observed suppression of pAKT, pPRAS40, pNDRG1, and pS6 (Fig. 3A) . In these tumors, expression of HMGCS1, IDI1, and SQLE was also modulated by day 7. To confirm the modulation of HMGCS1, IDI1, and SQLE in another tumor model, we examined protein changes in PC3 tumor xenografts. In this model, we previously observed that dosing AZD8186 in the presence of ABT (increases AZD8186 exposure by inhibiting cytochrome p450 mediated clearance) increased efficacy (18) . At the less efficacious dosing regimen of 100 mg/kg twice daily, PI3K pathway biomarkers were reduced, but HMGCS1 and IDI1 were unchanged. However, when dosed in the presence of ABT, which increases the duration of pathway suppression, downregulation of both proteins was observed (Fig. 3B) . Treating 786-0 tumor xenografts, a PTEN-null renal cell adenocarcinoma cell line, with AZD8186 results in significant antitumor activity (Fig. 4A) , and changes in FDG-PET uptake (18, 36) . This tumor is sensitive to AZD8186 at doses as low as 12.5 mg/kg. Examination of pathway biomarkers in this model showed that in addition to inhibition of pAKT, pPRAS40, pNDRG1, and pS6, downregulation of HMGCS1 and IDI1 was observed (Fig. 4B) . These in vivo observations were consistent in vitro; expression of HMGCS1 was downregulated in 2D and 3D cultures. However, the degree of downregulation was greater in 3D and correlated with growth suppression (Supplementary Fig. S8A ). 786-0 cells were insensitive to AZD8186 when grown in 2D, but sensitive in 3D culture conditions (Supplementary Fig. S8B ). Although the effects in tumor models can vary between models, modulation of the cholesterol pathway is evident when AZD8186 delivers antitumor benefit.
AZD8186 treatment modulates PDHK4 signaling and carbon metabolism pathways
As inhibition of PI3Kb reduces glucose uptake into cells, further changes associated with perturbation of cellular metabolism were explored (36) . Consistent with this, profiling of HCC70 tumors treated with AZD8186 revealed an increase in pyruvate dehydrogenase kinase 4 (PDHK4) expression (Supplementary Table S2 ). The roles of PDHK2 and PDHK4 have been reported to be relevant in starvation and diabetes, controlling hormones, steroids, and fatty acid levels (37) (38) (39) (40) . mRNA profiling revealed a large increase in PDHK4 when HCC70 cells were treated with AZD8186 ( AZD8186 inhibits phosphorylation of PI3K-AKT-mTOR protein pathway biomarkers and suppresses expression of cholesterol synthesis in vivo. A, HCC70 xenografts were dosed for 7 days twice daily with 25 mg/kg AZD8186. B, PC3 tumors were dosed until day 30 of a twice a day dosing treatment with AZD8186 alone at 100 mg/kg or AZD8186 at 30 mg/kg with ABT. Bar charts represent mean AE SEM biomarker signal from Western blotting (left y-axis) and AZD8186 plasma-free PK (red circles, right y-axis). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. n ¼ 3-5 animals/time point.
following AZD8186 treatment occurs as a result of feedback reactivation described in previous studies with PI3K isoformselective inhibitors ( Fig. 5B; refs. 21, 41) . In HCC70 cells, transient changes in PDHK4 and CPT1A protein were seen at 24 hours (Fig.  5B) . However, p-PDH was induced as early as 6 hours following AZD8186 treatment. In PTEN-null prostate cells lines, upregulation of PDHK4 protein was observed at 6 and 24 hours, as was p-PDH (Ser293 and Ser300; Fig. 5C ). Upregulation of Ser300 p-PDH was also observed in HCC70 tumors 6 hours after AZD8186 treatment (Fig. 5D ). The relevance of the PDHK4 changes was determined using real-time determination of oxygen consumption (OCR) by SeaHorse analysis (Fig. 5E) . No significant effect in OCR was observed after 200 minutes of AZD8186 treatment (data not shown). However, after 24 hours of treatment with AZD8186, OCR levels were significantly reduced in a dose-dependent manner in PTEN-null cell lines (Fig. 5E) . We also observed an expected decrease on extracellular acidification levels. Taken together, these results suggest that PI3Kb inhibition promotes additional modulation of metabolism through PDHK-4 upregulation.
The impact of AZD8186 treatment on the metabolic phenotype of treated cells was analyzed in vitro. LNCAP and HCC70 cells were treated with AZD8186 for 24 hours and the changes in key metabolites assessed in time-matched control samples. Hypothesis independent metabolite analysis revealed a number of changes ( Fig. 6A and C) . Intermediates associated with glycolysis were reduced (Fig. 6B and D) . Strikingly, in both cell lines, there was a marked decrease in deoxyribonucleotide triphosphates (dNTP) levels. The levels of amino acids increased in LNCAP cells and more modestly in HCC70 (Fig. 6B and D) . Because of detection limitations, we were unable to robustly measure changes in cholesterol biosynthesis pathway intermediates; however, changes in the levels of HMG-CoA were detected in LNCAP cells, and effects on CoA were detected in both cell lines (Supplementary Fig. S9) . Consistent with the reduction in the nucleotide pool, AZD8186-treated xenografts exhibit increases in the expression of replication stress and DNA damage biomarkers (42, 43) . In HCC70 tumors, we observe an induction in the phosphorylation of both RPA32 and g-H2AX (Fig. 6E) Metabolites that have QC CV <30%, P < 0.05, and log 2 (fold change) >0.5 are represented by the red star. Metabolites with P < 0.05 are represented by the red circle, and metabolites with P > 0.05 are represented by the white circle. The y-axis P values result from a univariate t test describing the statistical significance of a given metabolite in the binary group comparison. Bar charts (B and D) represent the log 2 fold change of specific metabolites. Error bars, SEM. Data are the average of six technical replicates and representative of two biological replicates. E, HCC70 xenografts were dosed for 1 day with 50 mg/kg AZD8186. Bar charts, mean AE SEM biomarker signal (left y-axis) and AZD8186 plasma-free PK (red circles, right y-axis). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. n ¼ 3-5 animals/time point.
previously shown an increase in phosphorylated g-H2AX in AZD8186-treated 786-0 and U87-MG tumor xenografts (36) . Collectively, these data establish that AZD8186 has significant roles in regulating the tumor metabolic phenotype.
Discussion
Here, we show that treating PTEN-null tumors with inhibitors of PI3Kb, such as AZD8186, has profound consequences on a number of critical cellular metabolism pathways. In addition to modulating canonical PI3K-AKT-mediated cell survival signaling, inhibition of PI3Kb in PTEN-null tumor models suppresses cholesterol biosynthesis pathway enzymes and changes levels of critical metabolites such as dNTPs, both of which are important for tumor cell proliferation and survival. In addition to the metabolomic experiments, Seahorse flux analysis demonstrated that AZD8186 decreases glycolysis rate. Collectively, the data are consistent with AZD8186 treatment driving a cellular stress phenotype associated with changes in lipid pathways and increases in DNA damage.
HMGCS1, the enzyme that determines the rate of entry of acetyl CoA into the cholesterol biosynthesis pathway consistently changed, but other enzymes in the pathway were differentially modulated. The effect in cell lines can vary, and presumably, the critical impact on each individual cell will be governed by both the mutation status and how the individual tumor cells have adapted critical pathways. Although inhibiting PI3Kb signaling modulates both FOXO3 and MYC, and FOXO3 can influence the expression of HMGCS1, the regulation was partial and it is likely that other mechanisms are involved in eliciting the PI3Kb response. For example, the SREBP transcription factors are critical mediators of cholesterol synthesis/import and regulated by PI3K/AKT signaling (44, 45) . Because of limitations in reagents, we have been unable to formally prove that SREBP signaling plays a role. However, preliminary data suggest that SREBP1 and SREBP2 modulate basal HMGCS1 expression in PTEN-null cell lines but whether PI3Kb regulates SREBP1/2 activity in this context is currently not clear due to concerns with the specificity of available antibodies to SREBP1/2 in our hands (data not shown). Further work is required to explore the specific effects in these different cell backgrounds, which will give further insight into the mechanism through which PI3Kb drives tumor progression.
PTEN deletion and TP53 mutation results in upregulation of the dependency on cholesterol (46, 47) . In a PTEN-null DLBCL line, sensitivity to a pan-PI3K inhibitor was associated with downregulation of certain proteins on the cholesterol biosynthesis pathway, in particular the regulation of HMGCS1, which was required for maintaining signaling through the BCR complex (48) . In PTEN WT tumors, alternative enzymes, such as SC4MOL, required to generate of C4-demethylated sterols, appear to be essential in maintaining EGFR function, with loss leading to receptor degradation and cell death (49) . The modulation of endogenous C4 sterol metabolites has also been shown to impact signaling through LXR, leading to further loss of cholesterol (50) . More recently, it has been shown in a panel of bladder cells lines that inhibition of oncogenic FGFR signaling through PI3Ka and AKT leads to downregulation of cholesterol biosynthesis genes (51) . Recently, a number of studies have highlighted the importance of increased de novo lipogenesis for survival and growth of cells with mutant PI3K and KRAS (52) (53) (54) . This provides additional evidence for the importance of key metabolic pathways for tumor progression. We have shown that PTEN-null cells respond to AZD8186 by reducing nucleotide levels and glycolysis pathway intermediates. The metabolite profiling method employed was not able to assess changes in cholesterol pathway intermediates. Changes in the way the cell utilizes lipids and cholesterol were apparent from two observations. First, AZD8186 caused accumulation of vesicles containing neutral lipids. Second, AZD8186 induced cell contraction or rounding, which was restored by supplementing media with soluble cholesterol intermediates. The cells analyzed in this study were dependent on cholesterol as atorvastatin reduced survival. However, simply adding cholesterol pathway intermediates was not sufficient to fully restore cell proliferation. Gaining specific insight into this biology would be important given the association of TP53 mutation and PTEN loss with dependency on cholesterol (46, 47) .
AZD8186 mediated reduction in dNTPs synthesis, which will also contribute to inducing a stressed phenotype and replication stress, restricting proliferation and survival potential (55, 56) . Recently, a study assessing effects of the pan-PI3K inhibitor BKM-120 has also demonstrated the critical reduction in nucleotides and the induction of DNA damage in BRCA-mutant, TP53-mutant tumors (55) . This highlights that PI3K inhibitors can induce multiple changes in tumor cells that will all contribute to cell death. The importance of each of these events to each specific PTEN-null cell line may vary and warrant further investigation.
We hypothesize that PTEN loss results in a metabolic switch resulting in high glycolytic rates and a dependency on high cholesterol to maintain high levels of protein turnover, DNA replication, and transcription. Taken together, our data indicate that PI3Kb inhibition results in significant metabolic collapse, including decreased glycolytic flux and flux into the TCA cycle and decreased acetyl-CoA levels, which are required to maintain cholesterol metabolism. It cannot be excluded that some effects are related to decreased cellular proliferation; however, changes in transcript and protein expression, as well as metabolites, are seen in vitro within hours of treatment. Impacting any of these processes is likely to have a negative effect on the tumor cells inducing metabolic stress, and reduces the ability to maintain critical signaling pathways required for growth and survival. When cells are treated with AZD8186, it does not induce a strong apoptotic induction in vivo or in vitro, even in tumor models where monotherapy AZD8186 treatment induces tumor stasis or regression (18) .
Collectively, these data suggest that significant metabolic shutdown is an additional impact following PI3Kb inhibition in PTEN-null cells. This may be contributing to the efficacy seen with these compounds in this segment. Reduction of cholesterol synthesis may also contribute to efficacy by engaging the STING pathway stimulating antitumor effects through the innate immune system (57) . An intriguing link between PI3Ka signaling and glycolysis regulation has been elucidated where IGF/PI3Ka mediated activation of RAC induced release of aldolase from the cytoskeleton control independent of AKT/mTOR signaling (58) . This modulation of intermediates to generate cholesterol can impact posttranslational modification of small GTPases, such as RAS and RAC (59) . Given the additional link between PI3Kb and RAC-mediated signaling, it will be interesting to determine whether this mechanism also contributes to PI3Kb-mediated growth in PTEN-null tumors. This also leads to consideration of alternate combination strategies for targeting such tumor, and the potential for combining PI3Kb inhibitors with other agents that 
